Ariose Capital Management LTD Bei Gene, Ltd. Transaction History

Ariose Capital Management LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 08, 2020	SELL	$121.84 - $173.19 $6.21 Million - $8.83 Million	-51,009 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$115.78 - $208.34 $5.91 Million - $10.6 Million	51,009 New	51,009 $8.46 Million
Q2 2018 Aug 03, 2018	SELL	$152.5 - $216.77 $14 Million - $20 Million	-92,080 Closed	0 $0
Q1 2018 May 02, 2018	BUY	$97.41 - $177.22 $8.97 Million - $16.3 Million	92,080 New	92,080 $15.5 Million
Q4 2017 Feb 09, 2018	SELL	$79.6 - $114.73 $4.19 Million - $6.03 Million	-52,600 Closed	0 $0
Q3 2017 Nov 02, 2017	SELL	$66.19 - $103.46 $9.33 Million - $14.6 Million	-141,009 Reduced 72.83%	52,600 $5.44 Million
Q2 2017 Jan 23, 2018	SELL	N/A	-5,000 Reduced 2.52%	193,609 $8.71 Million
Q1 2017 Jan 23, 2018	BUY	N/A	198,609	198,609 $7.27 Million

217

42.1M

106K

93.1K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $21B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Ariose Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Ariose Capital Management LTD with notifications on news.